A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Clinical trial NCT00950300 · COMPLETED

Trial details

NCT number

NCT00950300

Sponsor

Hoffmann-La Roche

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2009-10-16

Primary completion

2011-07-12

Enrollment

596

View on ClinicalTrials.gov